Arrowstreet Capital Limited Partnership Purchases 1,254,035 Shares of Haemonetics Corporation $HAE

Arrowstreet Capital Limited Partnership boosted its position in Haemonetics Corporation (NYSE:HAE) by 994.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,380,102 shares of the medical instruments supplier’s stock after buying an additional 1,254,035 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Haemonetics were worth $110,615,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. True Wealth Design LLC lifted its position in Haemonetics by 6,700.0% during the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 335 shares during the last quarter. Leonteq Securities AG acquired a new stake in shares of Haemonetics in the fourth quarter valued at about $30,000. EverSource Wealth Advisors LLC increased its stake in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares during the period. Kestra Advisory Services LLC bought a new position in shares of Haemonetics in the fourth quarter worth about $34,000. Finally, Bayforest Capital Ltd acquired a new position in shares of Haemonetics during the 4th quarter worth about $40,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Down 1.8%

HAE stock opened at $76.77 on Tuesday. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. The company has a market cap of $3.49 billion, a PE ratio of 38.00, a price-to-earnings-growth ratio of 1.57 and a beta of 0.55. The business’s 50-day simple moving average is $62.67 and its 200 day simple moving average is $67.25.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. During the same quarter in the prior year, the firm posted $1.24 EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, research analysts anticipate that Haemonetics Corporation will post 5.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on HAE shares. Weiss Ratings downgraded Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, May 21st. Mizuho lifted their price target on Haemonetics from $70.00 to $85.00 and gave the stock an “outperform” rating in a research report on Monday. Citigroup upped their price target on Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, May 28th. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $78.78.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.